Light-activatable cannabinoid prodrug for combined and target-specific photodynamic and cannabinoid therapy

Abstract. Cannabinoids are emerging as promising antitumor drugs. However, complete tumor eradication solely by cannabinoid therapy remains challenging. In this study, we developed a far-red light activatable cannabinoid prodrug, which allows for tumor-specific and combinatory cannabinoid and photodynamic therapy. This prodrug consists of a phthalocyanine photosensitizer (PS), reactive oxygen species (ROS)-sensitive linker, and cannabinoid. It targets the type-2 cannabinoid receptor (CB2R) overexpressed in various types of cancers. Upon the 690-nm light irradiation, the PS produces cytotoxic ROS, which simultaneously cleaves the ROS-sensitive linker and subsequently releases the cannabinoid drug. We found that this unique multifunctional prodrug design offered dramatically improved therapeutic efficacy, and therefore provided a new strategy for targeted, controlled, and effective antitumor cannabinoid therapy.

[1]  Kashif Azizuddin,et al.  The Peripheral Benzodiazepine Receptor in Photodynamic Therapy with the Phthalocyanine Photosensitizer Pc 4¶ , 2002, Photochemistry and photobiology.

[2]  A. Ligresti,et al.  Cannabinoid pharmacology in cancer research: A new hope for cancer patients? , 2016, European journal of pharmacology.

[3]  Pin Shao,et al.  In vivo type 2 cannabinoid receptor-targeted tumor optical imaging using a near infrared fluorescent probe. , 2013, Bioconjugate chemistry.

[4]  Zheng Huang,et al.  A Review of Progress in Clinical Photodynamic Therapy , 2005, Technology in cancer research & treatment.

[5]  Alain Wagner,et al.  Cleavable linkers in chemical biology. , 2012, Bioorganic & medicinal chemistry.

[6]  Erica M. Stec,et al.  A fluorescence-based thiol quantification assay for ultra-high-throughput screening for inhibitors of coenzyme A production. , 2008, Assay and drug development technologies.

[7]  G. Ellman,et al.  Tissue sulfhydryl groups. , 1959, Archives of biochemistry and biophysics.

[8]  Youngjae You,et al.  Far-Red Light Activatable, Multifunctional Prodrug for Fluorescence Optical Imaging and Combinational Treatment , 2014, Journal of medicinal chemistry.

[9]  Ling Yang,et al.  Tumor mitochondria-targeted photodynamic therapy with a translocator protein (TSPO)-specific photosensitizer. , 2015, Acta biomaterialia.

[10]  T. Sippel.  New fluorochromes for thiols: maleimide and iodoacetamide derivatives of a 3-phenylcoumarin fluorophore. , 1981, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[11]  S. Woo,et al.  Folate-PEG Conjugates of a Far-Red Light-Activatable Paclitaxel Prodrug to Improve Selectivity toward Folate Receptor-Positive Cancer Cells , 2017, ACS omega.

[12]  S. Ghosh,et al.  Use of maleimide-thiol coupling chemistry for efficient syntheses of oligonucleotide-enzyme conjugate hybridization probes. , 1990, Bioconjugate chemistry.

[13]  Xiaochao Ma,et al.  Synthesis of a reactive oxygen species responsive heterobifunctional thioketal linker. , 2015, Tetrahedron letters.

[14]  R. Hurst,et al.  Efficient activation of a visible light-activatable CA4 prodrug through intermolecular photo-unclick chemistry in mitochondria. , 2017, Chemical communications.

[15]  D. Bornhop,et al.  MBC94, a conjugable ligand for cannabinoid CB 2 receptor imaging. , 2008, Bioconjugate chemistry.

[16]  S. Woo,et al.  Far-Red Light-Activatable Prodrug of Paclitaxel for the Combined Effects of Photodynamic Therapy and Site-Specific Paclitaxel Chemotherapy. , 2016, Journal of medicinal chemistry.

[17]  Pin Shao,et al.  Multilayer photodynamic therapy for highly effective and safe cancer treatment. , 2017, Acta biomaterialia.

[18]  R. Jain,et al.  Photodynamic therapy for cancer , 2003, Nature Reviews Cancer.

[19]  Paul Baas,et al.  Photodynamic therapy in oncology. , 2006, The oncologist.

[20]  E. Cudaback,et al.  The Expression Level of CB1 and CB2 Receptors Determines Their Efficacy at Inducing Apoptosis in Astrocytomas , 2010, PloS one.

[21]  Xiang-Qun Xie,et al.  Alkylamides from Echinacea Are a New Class of Cannabinomimetics , 2006, Journal of Biological Chemistry.

[22]  X. Xie,et al.  Target-selective phototherapy using a ligand-based photosensitizer for type 2 cannabinoid receptor. , 2014, Chemistry & biology.

[23]  Eric A. Horne,et al.  NIR-mbc94, a fluorescent ligand that binds to endogenous CB(2) receptors and is amenable to high-throughput screening. , 2011, Chemistry & biology.

[24]  Samuel G. Awuah,et al.  Site-specific and far-red-light-activatable prodrug of combretastatin A-4 using photo-unclick chemistry. , 2013, Journal of medicinal chemistry.

[25]  L. Soroceanu,et al.  The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids , 2015, Journal of Neuroimmune Pharmacology.

[26]  B. Zerner,et al.  [8] Reassessment of Ellman's reagent , 1983 .

[27]  Samuel G. Awuah,et al.  Folate Receptor-Mediated Enhanced and Specific Delivery of Far-Red Light-Activatable Prodrugs of Combretastatin A-4 to FR-Positive Tumor , 2014, Bioconjugate chemistry.

[28]  R. Ganju,et al.  Cannabinoids as therapeutic agents in cancer: current status and future implications , 2014, Oncotarget.

[29]  T. Möller,et al.  Binding of NIR-conPK and NIR-6T to Astrocytomas and Microglial Cells: Evidence for a Protein Related to TSPO , 2009, PloS one.

[30]  J. Janjic,et al.  Cannabinoid CB2 receptor as a new phototherapy target for the inhibition of tumor growth. , 2014, Molecular pharmaceutics.

[31]  D. Nair,et al.  The Thiol-Michael Addition Click Reaction: A Powerful and Widely Used Tool in Materials Chemistry , 2014 .

[32]  P. Ferrara,et al.  Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. , 1996, Biochimica et biophysica acta.